Key clinical point: In patients with prostate cancer (PCa), use of pantoprazole and other proton pump inhibitors (PPIs) showed an association with an increased risk of being treated with androgen deprivation therapy (ADT) and increased prostate cancer-specific mortality (PCSM).
Major finding: Every 6 months of cumulative use of pantoprazole was associated with a 3% increased rate of being treated with ADT (P = .031). Treatment with all other PPIs vs. no treatment was associated with a 39% increased PCSM (P less than .0001). No association was observed with PCa diagnosis.
Study details: This large Canadian population-based cohort study included 21,512 men aged 66 years or older with prostate cancer between 1994 and 2016.
Disclosures: This study was supported by Institute for Clinical and Evaluative Sciences, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care. The authors declared no conflicts of interest.
Goldberg H et al. Prostate Cancer Prostatic Dis. 2020 Jul 8. doi: 10.1038/s41391-020-0248-9.